Challenges and Strategies for Influenza Response after COVID-19 Pandemic
Yang Jiaying,Lin Shuxia,Shu Yuelong
DOI: https://doi.org/10.1097/id9.0000000000000117
2024-01-01
Infectious Diseases & Immunity
Abstract:After the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) pandemic in March 2020, the implementation of the most effective interventions became a paramount public health priority in the global response to the COVID-19 pandemic, especially before vaccines were available. Several studies have demonstrated that nonpharmaceutical interventions (NPIs), such as social distancing, wearing facemasks, and school closures, can substantially control the transmission of respiratory infections, including severe acute respiratory syndrome, pandemic H1N1 in 2009, and the COVID-19 pandemic.[1–3] However, various respiratory infections have become more prevalent since the COVID-19 pandemic. Since 2021, the incidence of respiratory syncytial virus (RSV) has rapidly increased in numerous countries, including the United States,[4] Australia,[5] England,[6] Italy,[7] Germany,[8] and Switzerland.[9] In December 2022, 5 European countries, including France and the United Kingdom, reported an increase in group A streptococcal infections.[10] Since mid-October 2023, Chinese surveillance systems have observed an increasing trend in respiratory infections caused by Mycoplasma pneumoniae among children in northern China.[11] Moreover, the global landscape of seasonal influenza has been significantly affected by the COVID-19 pandemic, resulting in notable changes in its epidemic patterns (Figure 1).Figure 1: Global influenza activities since 2020. The timeline shows the advances in China and declaration by World Health Organization (WHO) against COVID-19. The panels from top to bottom represent the patterns of weekly influenza virus activities in northern hemisphere, southern hemisphere, northern China, southern China, United States, and Sweden, from week 14, 2019, to week 46, 2023. Different colors represent different influenza (sub)type. The arrows indicate the high points of the spring influenza season caused by influenza A(H1N1)pdm09 in Mainland China in 2023. Data from southern and northern China were reported by network laboratories in Mainland China. Data from the northern/southern hemisphere and other countries were based on laboratory-confirmed influenza activity reported by the WHO FluNet (https://www.who.int/tools/flunet).WHO has established a global influenza surveillance and response system since 1952 (https://www.who.int/initiatives/global-influenza-surveillance-and-response-system), and China has also set up a comprehensive influenza surveillance network since 2003 (https://ivdc.chinacdc.cn/cnic/en/). These surveillance systems facilitate timely monitoring of influenza activity and evolution. As shown in Figure 1, the seasonal influenza activity declined worldwide during the 2020–2021 influenza season and gradually resurged in late 2021 and early 2022. By the end of 2022, global influenza activity had substantially increased, surpassing pre–COVID-19 pandemic levels. Moreover, influenza B/Yamagata lineage virus has not been detected since April 2020, which may be due to the global COVID-19 response.[12] In early 2020, the onset of COVID-19 pandemic coincided with the traditional winter influenza season. In both southern and northern China, influenza activity peaked during the first week of January, rapidly declined thereafter, and decreased to a low level by the end of February. Despite a significant reduction in activity during the 2020 COVID-19 pandemic, no influenza peak was observed in China or other countries. In 2021, the influenza activity began to increase slowly. During the 2021/22 season, winter seasonal influenza activity peaked in January 2022; however, it remained below the average level observed prior to the COVID-19 pandemic, with almost all viruses detected belonging to the B/Victoria lineage. During the 2022/2023 influenza season, influenza activity continued to increase. In April 2022, southern provinces experienced a peak in influenza activity during the summer season, with influenza A(H3N2) virus being predominant. Minor fluctuations in influenza activity were observed in the northern provinces during summer and autumn. Toward the end of 2022, the Chinese government issued "20 measures" and "10 new measures" to optimize COVID-19 response. Simultaneously, the influenza activity rapidly declined to extremely low levels. By the end of February 2023, the influenza A(H1N1)pdm09 activity notably increased, peaking in mid-late March and gradually declining to a low level in April. This influenza activity was observed approximately 2 months later than the typical winter-spring influenza season prior to the COVID-19 pandemic, albeit with a higher intensity. No obvious summer influenza peaks were observed in 2023. However, influenza activity in southern and northern China has increased since September and October 2023, respectively, entering the autumn-winter influenza season nearly 2 months earlier than the winter influenza seasons before the COVID-19 pandemic. During this influenza season, the predominant circulating influenza strains in China were influenza A(H3N2), followed by the influenza B/Victoria lineage virus (Figure 1). During the COVID-19 pandemic, influenza activity and circulation patterns have changed globally. Since WHO declared the COVID-19 pandemic on March 11, 2020, influenza activity had sharply declined. However, it gradually increased during the winter and summer of 2021 in the northern and southern hemispheres, respectively, and returned to pre–COVID-19 levels in most regions after the 2022/2023 season. Interestingly, the resumption of influenza activity was not strictly associated with the zero strategy of the COVID-19 pandemic response. The United States and many European countries, such as Sweden, have reported influenza activity since the 2021 winter season, whereas China has reported influenza activity since the 2021 spring season (Figure 1). Although A(H1N1)pdm09, A(H3N2), and B influenza viruses cocirculate globally, B/Yamagata lineage viruses have not been detected since the beginning of the COVID-19 pandemic, and the predominant circulating virus varied in different regions. For example, in China, the influenza B/Victoria lineage virus predominated, followed by H3N2 and H1N1, whereas in the United States and Sweden, A(H3N2) was reported first, followed by the B/Victoria lineage (Figure 1). Notably, various subtypes of influenza viruses circulated within specific regions, and these viruses evolved in distinct geographic areas. For influenza B/Victoria lineage viruses, subclade 1A.3a.1 viruses with additional HA amino acid substitutions V220M and P241Q were almost exclusively detected in Mainland China and were predominant from November 2020. Subclade 1A.3a.2 viruses, characterized by additional HA amino acid substitutions A127T, P144L, and K203R, were first detected in January 2021 and were more prevalent than 1A.3a.1 from August 2021.[13,14] Antigenic differences were observed between viruses from subclades 1A.3a.1 and 1A.3a.2. Simultaneously, subclade 1A.3a.2 viruses have circulated in Asia, Africa, Europe, Oceania, and North America; however, they demonstrate further genetic divergence, with additional HA amino acid substitutions encoded in viruses from different geographic locations. Subclade 1A.3a.2 viruses from Mainland China exhibit a distinctive HA amino acid substitution, H122Q. In contrast, viruses from South Asia and Africa encode A202V. More recently, viruses from Africa, Asia, Europe, and North America have D197E, whereas a subset of previously circulating viruses from Africa, Europe, West Asia, and North America carries additional amino acid substitutions T182A, D197E, and T221A.[15–18] Subsequently, the 1A.3a.2 HA genes have predominated globally, including in China, with the majority sharing the substitution D197E in HA (Figure 2A).[19]Figure 2: The phylogenetic trees of influenza B/Victoria (A), A(H3N2) (B), and A(H1N1)pdm09 (C) viruses. The HA nucleotide sequences were downloaded from the GISAID database on December 28, 2023. Influenza B/Victoria virus strains were collected from 2020 to 2023; influenza A(H1N1)pdm09 and A(H3N2) virus strains were collected from 2022 to 2023. Clade classification of each influenza virus subtype is shown on the right side of the phylogenetic tree. The branches are colored by geographic region, according to the legend on the left. Maximum likelihood trees were generated using IQ-TREE (http://iqtree.cibiv.univie.ac.at/).The influenza A(H3N2) viruses have been increasingly detected since March 2022, replacing the B/Victoria lineage viruses as the dominant viruses during the 2022 summer season in China. Viruses from clade 3C.2a1b.2a.1 were predominant during this period, and viruses from subclade 1a.1 (typically encoding I48T and K171N substitutions in HA genes) were detected. Whereas the majority of viruses circulating in 2023 belong to clade 3C.2a1b.2a.2, HA genes (typically encoding Y159N, T160I, L164Q, G186D, and D190N substitutions) have evolved into multiple subclades (ie, 2a-2d), and subclade 2a.3a.1 (typically encoding E50K, D53N, N96S, I140K, I192F, I223V, and N378S) predominated in the mainland of China in 2023. Clades 3C.2a1b.2a.1 and 3C.2a1b.2a.2 are antigenically distinct. Clade 3C.2a1b.2a.2 predominated globally during 2022–2023, including 3 subclades: 2a.1b (typically encoding D53G, D104G, I140K, K276R, and R299K), 2a.3a.1, and 2b (typically encoding E50K, F79V, and I140K).[19–21] The various HA subclades have been found in different regions globally, and viruses with HA genes from multiple subclades cocirculate in several geographic regions in varying proportions. Of these, subclades 2a.3a.1 were globally predominant. Subclade 2a.1b viruses have mainly been detected in North America, Europe, and Oceania. Subclades 2a.3a.1 and 2b were detected globally (Figure 2B).[19–21] Influenza A(H1N1)pdm09 viruses have been detected in Mainland China since January 2023. The majority of the A(H1N1)pdm09 viruses had HA genes belonging to clade 6B.1A.5a.2. These viruses have further diversified into the designated subclades 6B.1A.5a.2a (with additional HA amino acid substitutions K54Q, A186T, Q189E, E224A, R259K, and K308R) and 6B.1A. 5a.2a.1 (with additional HA amino acid substitutions P137S, K142R, D260E, T277A, E356D, and N451H). Viruses of the subclade 6B.1A.5a.2a were predominant in Mainland China. Meanwhile, viruses within subclades 6B.1A.5a.2a and 6B.1A.5a.2a.1 cocirculated globally, with regional differences in proportions, and continued genetic diversification within both subclades. Subclade 6B.1A.5a.2a viruses were mainly detected in Oceania, Asia, Africa, and Europe, whereas subclade 6B.1A.5a.2a.1 viruses were mainly detected in Europe, North America, Central America, and South America.[19] Nevertheless, no antigenic differences were observed between viruses of the subclades 6B.1A.5a.2a and 6B.1A.5a.2a.1 (Figure 2C). Influenza surveillance data revealed that global implementation of NPIs during the COVID-19 pandemic significantly reduced influenza activity. Lei et al.[2,22] reported that NPIs for COVID-19 pandemic response in China reduced the influenza transmissibility by 34.6% (95% confidence interval, 31.3%–38.2%) in the epidemiological year 2019–2020 compared with epidemiological year 2018–2019. In epidemiological year 2021/2022, the reproduction number of influenza was reduced by 64.0% (in southern China) and 34.5% (in northern China), compared with those before the COVID-19 pandemic.[23] This scenario was also observed globally, although COVID-19 containment measurements varied in different regions, such as the United States, which experienced a rebound of respiratory diseases in the first winter after relaxing pandemic prevention and control measures. This demonstrates that NPIs can effectively reduce the transmission of respiratory infections at the population level, thereby reducing the burden of disease in the real world. However, with the adjustment of global containment measures, influenza activity began to increase again, gradually reaching or even exceeding the prepandemic levels. Several factors might have contributed to this observation. First, the protective antibody levels of the influenza virus acquired through infection or vaccination decayed rapidly, and the low influenza activity during the pandemic resulted in a decreased infection rate among the population, consequently increasing the number of susceptible individuals. One study showed that the proportion of individuals susceptible to the influenza virus increased by 138.6% and 57.3% in southern and northern China, respectively, by October 1, 2022.[23] Environmental factors may also contribute to the rebound in influenza activity. A previous study suggested that temperature is significantly correlated with influenza activity in China. In northern China, low temperatures elevated the risk of influenza-like illness, flu A, and flu B. However, in central and southern China, both low and high temperatures contributed to an increased risk of influenza-like illness and flu A, and only low temperatures heightened the risk of flu B.[24] One study indicated that in order to control the influenza epidemic to the prepandemic level after relaxing NPIs, the influenza vaccination rates in southern and northern China should increase to 53.8% and 33.8%, respectively. Thus, advocating influenza vaccination is crucial for mitigating potential influenza epidemics in the coming years.[23] The world has won the battle against the COVID-19 pandemic by implementing NPIs and massive population vaccinations. The WHO declared the end of the pandemic on May 5, 2023.[25] However, since 2022, the world has witnessed the effect of respiratory pathogens such as influenza virus, RSV, adenovirus, and M. pneumoniae. These pathogens have manifested with varying degrees of severity globally, posing significant threats to human health, especially among high-risk groups such as children and older adults. Therefore, promoting COVID and flu vaccinations in high-risk groups remains imperative. However, no vaccines exist against several important respiratory infections; therefore, it is important to continue calling for personal protection, particularly in special settings such as hospitals and nursing homes. Important pathogens causing respiratory infectious diseases, such as the influenza virus, are characterized by rapid mutations and host immune evasion. To address these challenges, we need to learn from the history of influenza prevention and control. First, increasing the influenza vaccination rate, especially in high-risk groups, is essential for reducing the influenza disease burden in China. Second, as antigenic differences exist between different regions, it is necessary to recommend influenza vaccine strains in China to improve vaccination efficacy. Third, surveillance between human-animal interfaces should be enhanced for timely monitoring of zoonotic influenza virus interspecies transmission to facilitate rapid influenza pandemic warning and response. Finally, research and development of universal vaccines and broad-spectrum antiviral drugs should be actively promoted to address the challenges posed by rapid influenza virus mutations. Although the COVID-19 pandemic has come to an end, emerging infectious diseases and subsequent pandemics are inevitable. Important respiratory pathogens, such as coronavirus and RSV, should be integrated into the current global influenza surveillance and response system. This will enable timely monitoring of viral mutations and the selection of appropriate viral strains for vaccine production to improve the protective efficacy of vaccines. This "killing multiple birds with one stone" strategy will help saving resources and monitoring multiple pathogens efficiently. Developing new diagnostic reagents, vaccines, and drugs can protect human health to the greatest extent possible, and the human health community requires the participation of every individual.